The most popular FierceBiotech stories of 2015

Alok Saboo FierceBiotech News

The most popular FiercePharma stories of 2015

Alok Saboo FiercePharma News

Dr. Reddy’s blasted in warning letter for hiding existence of testing lab from FDA

Eric Palmer An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to ...

Lilly’s middling lung cancer drug wins FDA approval with a restrictive label

Damian Garde Eli Lilly won FDA approval for a lung cancer treatment that posted only a marginal survival benefit in late-stage clinical trials, gaining clearance to treat a small population ...

Allergan CEO Saunders could cash out Pfizer deal with $187M, Bloomberg figures

Eric Palmer Even if Brent Saunders does not get the CEO role at Pfizer as a condition of Allergan agreeing to a buyout, which is reportedly being demanded, he will still get ...

Takeda’s ‘breakthrough’ Velcade heir wins early FDA approval in myeloma

Damian Garde Takeda Pharmaceutical's top cancer prospect won a speedy FDA approval, wading into a crowded market for multiple myeloma treatments with hopes of duplicating the success ...

Pfizer and Allergan wend toward a $150B merger, reports say

Tracy Staton Pfizer and Allergan are coming down to the wire on a merger that would be the biggest pharma deal ever. The all-stock transaction would be worth up to $ 150 billion, at ...

‘Pfizergan’ talks prompt new anti-tax inversion rules from Treasury

Tracy Staton The U.S. Treasury Department is rushing out a new set of guidelines on the "tax inversion" deals that have allowed drugmakers to save big money on taxes by buying ...

Stepped-up Nucynta sales push starts paying off for Depomed

Tracy Staton Depomed's relaunch of the Nucynta franchise–purchased earlier this year from Johnson & Johnson–is off to a running start, the company said last week ...

Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus

John Carroll Doug Williams is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen. Last July, Williams signed on as "employee number one" ...

J&J nabs an early OK for ‘breakthrough’ multiple myeloma blockbuster contender Darzalex

John Carroll Johnson & Johnson scored an early FDA approval for its "breakthrough" blockbuster contender daratumumab, earning a swift OK as a new treatment for multiple ...

Catalent stops production at French plant, brings in law enforcement after it twice detects tampering

Eric Palmer U.S.-based Catalent has halted production at a drug manufacturing facility in France at the request of regulators after several incidents in which it appears someone within ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS